AI assistant
Denali Therapeutics Inc. — Director's Dealing 2021
Aug 24, 2021
31637_dirs_2021-08-23_49f4eb11-767d-483b-a05a-e470dfc85003.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Denali Therapeutics Inc. (DNLI)
CIK: 0001714899
Period of Report: 2021-08-19
Reporting Person: Ho Carole (Chief Medical Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-08-19 | Common Stock | S | 1402 | $49.31 | Disposed | 165917 | Indirect |
| 2021-08-19 | Common Stock | S | 1144 | $49.91 | Disposed | 164773 | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 25000 | Indirect |
| Common Stock | 77792 | Direct |
Footnotes
F1: Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units.
F2: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $48.79 to $49.78 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3: Reflects the issuance of shares to the Rohatgi-Ho Family 2009 Revocable Trust in connection with the vesting of 5000 restricted stock units held by the Reporting Person.
F4: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee.
F5: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $49.80 to $50.10 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F6: The shares are held of record by The Rohatgi-Ho Irrevocable GST Trust for the benefit of the Reporting Person's children.
F7: Includes 75,906 restricted stock units.
F8: Includes 410 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan purchased on June 1, 2021.